


Financial Tear Sheet

Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$17.82
Change (%)	▼ 0.18 (1.00%)
Volume	54,888
52 Week Low	\$13.23
Market Cap	\$345,879,197
Rolling EPS	-6.70
PE Ratio	0
Shares Outstanding	19,409,607
Data as of 02/16/18 3:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

News & Events

Date	Title
02/14/18	Merus Announces \$55.8 Million Private Placement Offering of Common Stock

Date	Title
02/22/18	RBC Capital Markets 2018
11:00 a.m. ET	Global Healthcare Conference
	Location New York, NY

02/05/18 Merus Announces Participation in Four Investor Conferences in February 2018

01/26/18 Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations

SEC Filings

Filing Date	Form
02/16/18	6-K
02/13/18	SC 13G/A
02/08/18	SC 13G
02/02/18	SC 13G/A

Primary IR Contact

Kimberly Minarovich
Argot Partners
Phone: 1 212-600-1902
E-mail: kimberly@argotpartners.com

Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Mark Iwicki	Chairman, Non-Executive Director
Wolfgang Berthold, Ph.D.	Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
Lionel Carnot	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive Director

Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO